NeoDynamics AB (publ) Third quarter Jul-Sep 2019
During the third quarter NeoDynamics developed according to plan. After the end of the quarter the new version of NeoDynamics biopsy system NeoNavia received regulatory approval in the EU and attracted great interest at the annual British radiology congress. The convertible loan was subscribed to an amount of ca SEK 15 million.Regulatory approval! Third quarter 2019 · Revenue amounted to SEK 4.581 m (3.749 m), including capitalized costs of SEK 4.469 m (3.734 m). During the quarter, the company had minor sales of materials. · Loss after tax amounted to SEK -4.477 m (-3.968 m).